J. Custodio

发表

Quantitation of intracellular triphosphate metabolites of antiretroviral agents in peripheral blood mononuclear cells (PBMCs) and corresponding cell count determinations: review of current methods and challenges

T. Tarnowski, Deqing Xiao, K. H. Ling, 2018, Expert opinion on drug metabolism & toxicology.

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

F. Post, M. Ramgopal, M. Fisher, 2014, HIV clinical trials.

Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single‐tablet regimen for the treatment of HIV infection

B. Kearney, A. Cheng, S. Ramanathan, 2014, Journal of clinical pharmacology.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

K. Lichtenstein, F. Post, Samir K. Gupta, 2016, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

B. Kearney, S. Ramanathan, M. Fordyce, 2016, Antimicrobial Agents and Chemotherapy.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

J. Gallant, M. Das, P. Tebas, 2017, Journal of acquired immune deficiency syndromes.

Predicting drug absorption and the effects of food on oral bioavailability

Leslie Z. Benet, Chi-Yuan Wu, L. Benet, 2006 .

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.

Leslie Z Benet, Chi-Yuan Wu, L. Benet, 2008, Advanced drug delivery reviews.

Effect of food on the pharmacokinetics of emtricitabine/rilpivirine/tenofovir disoproxil fumarate single‐tablet regimen

B. Kearney, S. Ramanathan, D. Pugatch, 2012 .

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

K. White, H. Stellbrink, P. Sax, 2017, The Lancet.

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

K. Tashima, A. Brochot, T. van de Casteele, 2014, AIDS Research and Therapy.

Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.

I. Mcnicholl, D. Piontkowsky, J. Custodio, 2016, AIDS reviews.

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

B. Kearney, H. Cao, J. Flaherty, 2017, Pharmacology research & perspectives.

Pharmacokinetics of cobicistat boosted‐elvitegravir administered in combination with rosuvastatin

B. Kearney, A. Cheng, A. Ray, 2014, Journal of clinical pharmacology.

P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir

B. Kearney, Xuelian Wei, E. Quirk, 2017 .

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision

K. Giacomini, X. Chu, Caroline A. Lee, 2018, Clinical pharmacology and therapeutics.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes

H. Hunt, J. Custodio, K. Donaldson, 2020, Journal of clinical pharmacology.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

J. Rockstroh, E. Daar, J. Molina, 2018, The lancet. HIV.

Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance

R. D. Bruce, G. Friedland, B. Kearney, 2013, Antimicrobial Agents and Chemotherapy.

The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment

R. D. Bruce, G. Friedland, B. Kearney, 2013, Journal of acquired immune deficiency syndromes.

Population Pharmacokinetics of Boosted‐Elvitegravir in HIV‐Infected Patients

Lijie Zhong, S. Ramanathan, T. Gordi, 2016, Journal of clinical pharmacology.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.

744 TENOFOVIR DF (TDF) IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH PRE-EXISTING MILD RENAL IMPAIRMENT

A. Horban, E. Gane, G. Subramanian, 2013 .

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults

K. Tashima, A. Brochot, T. Kakuda, 2014, Journal of the International AIDS Society.

Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers

G. Golor, H. Schran, O. Yin, 2011, Journal of clinical pharmacology.

Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection

Jia Hao, Jianhong Wang, S. Lazerwith, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

B. Kearney, S. Ramanathan, Xuelian Wei, 2016, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

B. Kearney, S. Ramanathan, M. Rhee, 2014, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals

M. Das, R. Begley, B. Kearney, 2018, Journal of acquired immune deficiency syndromes.

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.